[2015-May-27] FDA Approves Viberzi (eluxadoline) for Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults

[2015-May-27] FDA approves two therapies to treat IBS-D

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm448328.htm

Viberzi.cdx

Henry J. Breslin, Craig J. Diamond, Robert W. Kavash, Chaozhong Cai, Alexey B. Dyatkin, Tamara A. Miskowski, Sui-Po Zhang, Paul R. Wade, Pamela J. Hornby, and Wei He, Identification of a dual δ OR antagonist/μ OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d), Bioorg. Med. Chem. Lett., 2012, 22 (14), pp 4869-4872

http://dx.doi.org/10.1016/j.bmcl.2012.05.042

Roberto De Giorgio, Giovanni Barbara, John B. Furness, and Marcello Tonini, Novel therapeutic targets for enteric nervous system disorders, Trends Pharmacol. Sci., 2007, 28 (9), pp 473-481

http://dx.doi.org/10.1016/j.tips.2007.08.003

Sylvie Bradesi, and Emeran A Mayer, Novel therapeutic approaches in IBS, Curr. Opin. Pharmacol., 2007, 7 (6), pp 598–604

http://dx.doi.org/10.1016/j.coph.2007.09.012

Michael Camilleri, Drug development and IBS drugs: experience from the past, current challenges, and proposal for the future, Curr. Opin. Pharmacol., 2008, 8 (6), pp 671–676

http://dx.doi.org/10.1016/j.coph.2008.06.001

Howard Y. Chang, and Anthony J. Lembo, Opioid-induced bowel dysfunction, Curr. Treat. Options Gastroenterol., 2008, 11 (1), pp 11-18

http://dx.doi.org/10.1007/s11938-008-0002-1

Joseph Y. Chang, and Nicholas J. Talley, Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment, Trends Pharmacol. Sci., 2010, 31 (7), pp 326–334

http://dx.doi.org/10.1016/j.tips.2010.04.008

Michael Camilleri, Peripheral Mechanisms in Irritable Bowel Syndrome, N. Engl. J. Med., 2012, 367 (17), pp 1626-1635

http://dx.doi.org/10.1056/NEJMra1207068

Michael Camilleri, Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome, Expert Opin. Pharmacol., 2013, 14 (9), pp 1151-1160

http://dx.doi.org/10.1517/14656566.2013.794223

Jose L. Barboza, Nicholas J. Talley, and Baharak Moshiree, Current and Emerging Pharmacotherapeutic Options for Irritable Bowel Syndrome, Drugs, 2014, 74 (16), pp 1849-1870

http://dx.doi.org/10.1007/s40265-014-0292-7